ACDC · Project

Programmable Artificial Cells That Produce Compounds On Demand for Medicine and Environment

healthPrototypeTRL 3Thin data (2/5)

acdch2020.eu

Imagine tiny artificial cells that work like apps on your phone — you tell them what chemical to make, and they produce it. The team built microscale compartments that mimic how real cells organize their internal chemistry, with different "rooms" that talk to each other just like organelles do inside living cells. They used microfluidics (think: plumbing at the scale of a human hair) and DNA-based assembly to create these programmable capsules. The long-term goal is on-demand production of medicines, environmental cleanup agents, or threat-detection sensors.

By the numbers

EUR 4,376,295

EU funding for artificial cell technology development

consortium partners across academia and industry

countries involved (CH, FR, IT, UK)

total project deliverables produced

years of collective start-up enterprise experience in the team

industry partners including SMEs

The business problem

What needed solving

Companies in pharma, environmental services, and biosecurity need precise, programmable ways to produce chemical compounds, detect biological threats, or deliver targeted treatments — but current methods are bulky, inflexible, and cannot be reconfigured on the fly. There is no off-the-shelf technology that mimics living cells' ability to compartmentalize, communicate, and adapt their chemistry at microscale.

The solution

What was built

The project built functional artificial cell constructs using microfluidic technology, including demonstrated prototypes: x-phase x-core L2 capsules and 2-phase x-core L2 capsules. These are microscale compartmentalized structures that mimic cell organelle communication, supported by DNA-based assembly and a multi-level mathematical model. A total of 22 deliverables were produced across the 4+ year project.

Audience

Who needs this

Pharmaceutical companies developing point-of-care theranostic devicesEnvironmental remediation firms needing programmable biological cleanup agentsDefense contractors building portable bioagent detection systemsBiotech startups working on cell-free protein production platformsMedical device companies exploring microfluidic diagnostic tools

Business applications

Who can put this to work

Pharmaceuticals & Personalized Medicine

enterprise

Target: Pharma companies developing point-of-care diagnostics or personalized drug delivery

If you are a pharmaceutical company struggling with one-size-fits-all drug delivery — this project developed programmable artificial cell capsules that can compartmentalize and produce compounds on demand. The technology could enable theranostic devices that both diagnose and treat at the patient level. The consortium included 2 industry partners and drew on 55 years of collective start-up experience to explore commercial translation.

Environmental Services & Bioremediation

mid-size

Target: Companies providing environmental cleanup or water treatment solutions

If you are an environmental services company dealing with contaminated sites that need targeted biological treatment — this project built artificial cell constructs designed for sensing and actuation in environments for bioremediation. The microfluidic platform enables precise chemical compartmentalization that could be programmed to break down specific pollutants. The project ran for over 4 years with EUR 4,376,295 in EU funding across 6 partners in 4 countries.

Defense & Biosecurity

enterprise

Target: Security firms or government contractors developing biological threat detection

If you are a defense or biosecurity company needing rapid field-deployable bioagent detection — this project developed microscale chemical compartments with inter-compartmental communication that could serve as biological threat sensors. The capsule technology demonstrated in deliverables (x-phase, x-core L2 capsules and 2-phase, x-core L2 capsules) represents building blocks for programmable detection devices. The consortium spans 4 countries (CH, FR, IT, UK) with both academic and industrial expertise.

Frequently asked

Quick answers

What would it cost to license or adopt this technology?

The project was funded with EUR 4,376,295 under Horizon 2020 as a Research and Innovation Action. Licensing terms would need to be negotiated with the coordinator (Università degli Studi di Trento) and relevant consortium partners. Based on available project data, the team explicitly aimed to translate intellectual property into commercial advantage.

Can this scale to industrial production volumes?

The technology is currently at laboratory and microfluidic scale. The project focused on building functional proof-of-concept artificial cell constructs, not industrial-scale manufacturing. Scaling from lab-on-a-chip to production volumes would require significant additional development and engineering.

Who owns the intellectual property?

IP generated during the project is owned by the 6-partner consortium led by Università degli Studi di Trento (Italy). The consortium includes 2 industry partners and 2 SMEs across 4 countries (CH, FR, IT, UK). The objective explicitly mentions exploring translation of new IP into commercial advantage.

How far is this from a real product?

This was a FET Proactive project focused on future and emerging technologies — meaning it is early-stage research. The demonstrated deliverables include capsule prototypes (L2 capsules in different configurations). Moving to a product would require further development, regulatory approval, and manufacturing scale-up.

What exactly was demonstrated?

The project delivered 22 deliverables total, including demonstrated x-phase x-core L2 capsules and 2-phase x-core L2 capsules. These represent functional artificial cell compartments with controlled architecture. The work also produced a multi-level mathematical model of the system.

Is this compliant with existing regulations?

Based on available project data, the team considered ethical dimensions as part of their outreach and engagement programme. However, artificial cell technology for medical or environmental applications would face significant regulatory hurdles (EMA, EPA equivalent) that are not yet addressed at this stage.

What support is available for companies wanting to adopt this?

The consortium has 55 years of collective start-up enterprise experience and explicitly aimed to explore commercial translation. The 2 industrial partners and 2 SMEs in the consortium could potentially serve as development or integration partners. Contact would go through the coordinating university in Trento.

Consortium

Who built it

The ACDC consortium brings together 6 partners from 4 countries (Switzerland, France, Italy, UK), with a healthy mix of 3 universities, 1 research organization, and 2 industry partners (both SMEs). The 33% industry ratio is notable for a fundamental research project and signals genuine interest in commercial translation. Led by Università degli Studi di Trento in Italy, the team claims 55 years of collective start-up experience — unusual for an academic-heavy project. The EUR 4,376,295 budget over 4+ years funded 22 deliverables. For a business looking to engage, the SME partners would be the most natural entry point for technology licensing discussions, while the academic partners hold deep expertise in microfluidics and synthetic biology.

UNIVERSITA DEGLI STUDI DI TRENTOCoordinator · IT
ELVESYSparticipant · FR
EXPLORA SRLparticipant · IT
MUSEO DELLE SCIENZEparticipant · IT
ZURCHER HOCHSCHULE FUR ANGEWANDTE WISSENSCHAFTENparticipant · CH
CARDIFF UNIVERSITYparticipant · UK

How to reach the team

Università degli Studi di Trento, Italy — use SciTransfer's coordinator lookup service to find the project lead's direct contact

Order a report on this consortium See UNIVERSITA DEGLI STUDI DI TRENTO profile →

Next steps

Talk to the team behind this work.

Want to explore how programmable artificial cell technology could solve your compound production or detection challenges? SciTransfer can connect you directly with the ACDC research team and help you evaluate licensing opportunities.

Order a report on this topic More in Health & Biomedical